Item 3.01 Notice of Delisting or Failure to Satisfy a Continued Listing Rule or
Standard; Transfer of Listing.
On December 30, 2022, Finch Therapeutics Group, Inc. (the "Company") received a
deficiency letter from the Listing Qualifications Department of The Nasdaq Stock
Market LLC ("Nasdaq") notifying the Company that, for the last 30 consecutive
business days, the bid price for the Company's common stock, par value $ 0.001
per share (the "Common Stock"), had closed below the $1.00 per share minimum bid
price requirement for continued inclusion on the Nasdaq Global Select Market
pursuant to Nasdaq Listing Rule 5450(a)(1) (the "Bid Price Requirement").
The deficiency letter has no immediate effect on the listing of the Common Stock
on the Nasdaq Global Select Market. In accordance with Nasdaq Listing Rule
5810(c)(3)(A), the Company has been provided an initial compliance period of 180
calendar days from receipt of the deficiency letter, or until June 28, 2023, to
regain compliance with the Bid Price Requirement. To regain compliance, the
closing bid price for the Common Stock must be at least $1.00 per share for a
minimum of 10 consecutive business days prior to June 28, 2023, unless Nasdaq
exercises its discretion to extend this period pursuant to Nasdaq Listing Rule
5810(c)(3)(H). There can be no assurance the Company will be able to regain
compliance.
If the Company does not regain compliance with the Bid Price Requirement by June
28, 2023, the Company may be eligible for an additional 180 calendar day
compliance period. To qualify, the Company must submit an application to
transfer the listing of the Common Stock to The Nasdaq Capital Market, which
requires the Company to meet the continued listing requirement for the market
value of publicly held shares and all other initial listing standards for The
Nasdaq Capital Market, other than the Bid Price Requirement. The Company would
also need to pay an application fee to Nasdaq and will need to provide written
notice of its intention to cure the deficiency during the additional compliance
period. As part of its review process, Nasdaq will make a determination of
whether it believes the Company will be able to cure this deficiency.
If the Company does not regain compliance within the compliance period(s),
Nasdaq will provide written notification to the Company that the Common Stock
will be subject to delisting. At that time, the Company may appeal the delisting
determination to a Nasdaq Listing Qualifications Panel. There can be no
assurance that, if the Company decides to appeal the delisting determination,
such appeal would be successful.
The Company intends to monitor the closing bid price of the Common Stock and
may, if appropriate, consider available options to regain compliance with the
Bid Price Requirement, including, subject to approval of the Company's Board of
Directors and stockholders, implementing a reverse stock split. There can be no
assurance that a reverse stock split would be approved or would result in a
sustained higher stock price that would allow the Company to regain compliance
with the Bid Price Requirement.
--------------------------------------------------------------------------------
© Edgar Online, source Glimpses
FINCH THERAPEUTICS GROUP, INC. 
